Terveystalo Oyj, a leading healthcare service provider in Finland, has demonstrated robust financial performance in its Q3 2024 interim report. The company reported a 5% increase in revenue to EUR 296 million and a remarkable 62% surge in adjusted EBITA to EUR 34 million, representing 11.6% of revenue. The healthcare services segment, a key driver of this growth, saw an 11% rise in revenue to EUR 232 million, bolstered by a strong supply, improved sales mix, and successful commercial operations.

Comparatively, the company's performance has improved consistently over the past quarters. The profit improvement program, initiated in late 2022, has exceeded expectations, contributing significantly to the financial results. Despite a 10% drop in the portfolio businesses' revenue, profitability improved, with adjusted EBITA rising by 70% to EUR 3 million.

The Swedish segment faced challenges with a 10% revenue decline, attributed to expired contracts and weakened demand. However, efforts to adjust the cost structure and enhance operational efficiency are underway, with a turnaround expected by early 2025.

Overall, Terveystalo's strategic focus on operational efficiency, medical quality, and value-creating services has strengthened its core business, positioning the company for future growth. The adjusted EBITA margin guidance for 2024 has been raised to 12-12.5%, reflecting confidence in meeting financial targets ahead of schedule.

For investors, Terveystalo's performance indicators suggest a solid foundation for continued profitability. The company's ability to adapt and improve operational efficiency amid market challenges indicates a resilient and promising investment opportunity.